Cognition Therapeutics, Inc. (NASDAQ:CGTX) Sees Large Drop in Short Interest

Cognition Therapeutics, Inc. (NASDAQ:CGTX - Get Free Report) was the recipient of a significant decline in short interest during the month of March. As of March 31st, there was short interest totalling 150,200 shares, a decline of 34.2% from the March 15th total of 228,100 shares. Based on an average daily volume of 204,700 shares, the days-to-cover ratio is presently 0.7 days. Currently, 0.5% of the company's stock are short sold.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Baird Financial Group Inc. purchased a new position in shares of Cognition Therapeutics during the first quarter worth approximately $56,000. Frontier Wealth Management LLC acquired a new position in Cognition Therapeutics in the first quarter valued at $152,000. Worth Venture Partners LLC purchased a new stake in shares of Cognition Therapeutics in the first quarter valued at about $473,000. Vanguard Group Inc. boosted its stake in shares of Cognition Therapeutics by 465.7% during the third quarter. Vanguard Group Inc. now owns 401,203 shares of the company's stock worth $762,000 after buying an additional 330,283 shares during the period. Finally, Two Sigma Investments LP purchased a new position in shares of Cognition Therapeutics during the third quarter worth about $46,000. Institutional investors and hedge funds own 43.35% of the company's stock.

Wall Street Analyst Weigh In

CGTX has been the topic of several recent analyst reports. B. Riley reiterated a "buy" rating and issued a $5.00 price target on shares of Cognition Therapeutics in a research note on Thursday, March 28th. Oppenheimer reaffirmed an "outperform" rating and issued a $9.00 target price on shares of Cognition Therapeutics in a research report on Wednesday, March 27th.

Cognition Therapeutics Stock Down 6.2 %

Shares of Cognition Therapeutics stock traded down $0.13 on Friday, hitting $1.96. The stock had a trading volume of 253,497 shares, compared to its average volume of 207,764. Cognition Therapeutics has a 52-week low of $0.90 and a 52-week high of $3.49. The company's 50 day moving average price is $1.99 and its 200 day moving average price is $1.70.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex for the treatment of Alzheimer's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.